Trial Profile

Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Angiotensin II (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections
Focus Therapeutic Use
Acronyms ACES

Most Recent Events

03 Aug 2021 Planned End Date changed from 1 May 2021 to 31 Dec 2022.
03 Aug 2021 Planned primary completion date changed from 1 May 2021 to 31 Jul 2022.
03 Jun 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com